论文部分内容阅读
目的观察晚期胃癌草酸铂/替吉奥(SOX方案)一线化疗后继续替吉奥维持化疗的疗效与不良反应。方法 59例初治的晚期胃癌患者采用SOX方案一线化疗,最多6个周期化疗后疗效评价无疾病进展的患者中,21例进行替吉奥维持化疗(A组),20例仅接受定期随访观察(B组)。结果 59例患者中完全缓解1例,部分缓解27例,稳定13例,有效率47.5%,疾病控制率69.5%。A组中位疾病进展时间(TTP)较B组延长(7.8个月vs.5.3个月)(P<0.05),两组总生存期(OS)差异无统计学意义(P>0.05)。维持化疗期间不良反应主要为Ⅰ-Ⅱ度的恶心、呕吐、骨髓抑制。结论SOX方案一线化疗后继续替吉奥维持化疗晚期胃癌可延长TTP,且安全性良好。
Objective To observe the curative effect and side effects of chemotherapy with oxaliplatin and tioguanil (SOX regimen) in patients with advanced gastric cancer after first-line chemotherapy. Methods Fifty-nine patients with newly diagnosed advanced gastric cancer undergoing first-line chemotherapy with SOX regimen and 21 patients with maintenance-free chemotherapy (group A) with no disease progression after up to 6 cycles of chemotherapy were enrolled. Only 20 patients were followed up (Group B). Results In 59 patients, 1 patient was completely relieved, 27 patients were partly relieved, and 13 patients were stable. The effective rate was 47.5% and the disease control rate was 69.5%. The median time to progression (TTP) in group A was longer than that in group B (7.8 months vs. 5.3 months) (P <0.05). There was no significant difference in the overall survival (OS) between the two groups (P> 0.05). Maintain adverse reactions during chemotherapy mainly Ⅰ-Ⅱ degree of nausea, vomiting, bone marrow suppression. CONCLUSIONS: The continued maintenance of TTP in patients with advanced gastric cancer after the first-line chemotherapy of SOX regimen is safe and safe.